Drug
Srp 1003 Infusion
Srp 1003 Infusion: highest development phase Phase 1/2, developed by Sarepta Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Sarepta Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| SRP-1003 IV Infusion NCT06138743 | Phase 1/2 | Myotonic Dystrophy 1 |
Latest
No recent events.
Follow Srp 1003 Infusion on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.